-
NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports
•
The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two electronic certificates: the “Certificate for Exporting APIs to the EU” and the “Exporting Certificate of a Pharmaceutical Product.” These certificates aim to streamline the export process and enhance regulatory compliance. Details of the Certificates
-
I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies
•
China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to accelerate biomarker-driven clinical studies and explore the cutting edge of companion diagnostics (CDx) development. Financial details of the partnership were not disclosed. Clinical and Development ContextWith the deepening of research on tumor pathogenesis, immunotherapy, particularly…
-
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
•
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a pre-IPO financing round. The funding was led by Gree Financial Investment and KingRay Capital, with additional participation from Efung Capital, China Medical System Holdings (CMS; HKG: 0867), Wuxi Guolian Development (Group), and other investors. Technology…
-
Alibaba Health Reports 22.9% Revenue Growth in H1 2022
•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the first half of 2022 (ended September 30, 2022), recording total revenues of RMB 11.5 billion (USD 1.6 billion), representing a 22.9% year-on-year (YOY) increase. Business PerformanceAliHealth’s self-operated pharmaceutical direct sales business generated RMB 10.01 billion…
-
3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million
•
China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO) of 16.35 million shares on the Hong Kong Stock Exchange. The share price is expected to range from HKD 22.96 to 26.24 (USD 2.94 to USD 3.36) per share, with a maximum gross take-home of…
-
China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact
•
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has released its summary of China’s trading situation in the health sphere during the first three quarters of 2022. According to Chinese government customs statistics, China recorded a medical product trade surplus in the period,…
-
Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau
•
China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to launch Bentrio nasal spray in Hong Kong and Macau. Under the agreement, DKSH HK will provide full-agency services, including key account management, marketing promotions, supply chain, and distribution for Bentrio Nasal Spray sales operations in…
-
Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss firm ADC Therapeutics SA. Under the agreement, Biocytogen will grant ADC Therapeutics a license to evaluate its proprietary antibodies against three tumor targets. ADC Therapeutics will have the option to license selected antibodies at a…
